Skip to main
NXTC
NXTC logo

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NextCure Inc. has secured global rights to SIM0505 outside of Greater China, which could yield up to $745 million in upfront and milestone payments, alongside tiered royalties that could reach double-digit percentages on net sales. The company is also focusing on its ADCs, which are projected to contribute positively despite a reassessment of other product candidates, reflecting a strategic pivot that enhances their overall value. Promising preclinical data indicates robust anti-tumor activity and a favorable safety profile for SIM0505, further supporting NextCure's strong pipeline and potential for future growth.

Bears say

NextCure Inc. has experienced a significant reduction in its projected enterprise value, which has decreased from $75 million to $37.5 million, contributing to a lower price target of $15. The clinical-stage biopharmaceutical company faces inherent risks associated with its therapies, including the potential for those therapies to fail during clinical trials. Additionally, the company's need to seek partnerships for its various programs may indicate challenges in securing necessary funding and support, further compounding the negative outlook on its stock.

Nextcure (NXTC) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Buy based on their latest research and market trends.

According to 2 analysts, Nextcure (NXTC) has a Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.